Table 1 Baseline characteristics (N=98)
Characteristics | Tumor and active TB, n (%) | Tumor and latent TB, n (%) | Tumor and obsolete TB, n (%) |
|---|---|---|---|
Median age (range) | 62 (29–72) | 65 (51–81) | 66 (22–80) |
Men | 40 (88.9) | 20 (95.2) | 31 (96.9) |
Smoking | |||
 Current/former | 29 (64.4) | 17 (80.9) | 26(81.3) |
 Never | 16 (35.6) | 4 (19.1) | 6 (18.7) |
Cancer types | |||
 NSCLC | 32 (71.1) | 18 (85.6) | 28(87.5) |
 SCLC | 1 (2.2) | 1 (4.8) | 4 (12.5) |
 ESCC | 7 (15.6) | 1 (4.8) | 0 |
 CSCC | 1 (2.2) | 0 | 0 |
 HNSCC | 1 (2.2) | 0 | 0 |
 HCC | 2 (4.5) | 0 | 0 |
 BC | 1 (2.2) | 0 | 0 |
 RC | 0 | 1 (4.8) | 0 |
Stage | |||
 III | 11 (24.4) | 9 (42.9) | 6 (18.7) |
 IV | 34 (75.6) | 12 (57.1) | 26 (81.3) |
ICI therapy | |||
 Adjuvant | 2 (4.4) | 2 (9.5) | 3 (9.4) |
 1st line | 21 (46.7) | 15 (71.4) | 21 (65.6) |
 2nd line | 16 (35.6) | 3 (14.3) | 6 (18.7) |
 3rd line | 6 (13.3) | 1 (4.8) | 2 (6.3) |
Treatment regimen | |||
 Anti-PD-(L)1 monotherapy | 12 (26.7) | 2 (9.5) | 8 (25.0) |
 Anti-PD-(L)1 + chemotherapy | 33 (73.3) | 19 (90.5) | 24 (75.0) |
PD-L1 status | |||
 Positive | 8 (17.8) | 5 (23.8) | 13 (40.6) |
 Negative | 4 (8.9) | 2 (9.5) | 4 (12.5) |
 Unknown | 33 (73.3) | 14 (66.7) | 15 (46.9) |
Diagnosis of TB | |||
 Clinical | 5 (11.1) | 0 | 0 |
 Bacteriologic | 36 (80) | 0 | 0 |
 Pathologic | 4 (8.9) | 0 | 0 |
 Immunological | 0 | 21 (100) | 0 |
 Radiological | 0 | 0 | 32 (100) |